Targeted Complement Inhibitors Protect against Posttransplant Cardiac Ischemia and Reperfusion Injury and Reveal an Important Role for the Alternative Pathway of Complement Activation

Carl Atkinson, Songqing He, Keeley Morris, Fei Qiao, Sarah Casey, Martin Goddard and Stephen Tomlinson

J Immuno published online 20 October 2010
http://www.jimmunol.org/content/early/2010/10/20/jimmunol.101504

Subscription Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Targeted Complement Inhibitors Protect against Posttransplant Cardiac Ischemia and Reperfusion Injury and Reveal an Important Role for the Alternative Pathway of Complement Activation

Carl Atkinson,*† Songqing He,*† Keeley Morris,* Fei Qiao,* Sarah Casey,* Martin Goddard,‡ and Stephen Tomlinson*

Ischemia reperfusion injury (IRI) is an unavoidable event during solid organ transplantation and is a major contributor to early graft dysfunction and subsequent graft immunogenicity. In a therapeutic paradigm using targeted complement inhibitors, we investigated the role of complement, and specifically the alternative pathway of complement, in IRI to heart isografts. Mouse heterotopic isograft heart transplants were performed in C57BL/6 mice treated with a single injection of either CR2-Crry (inhibits all complement pathways) or CR2-III (inhibits alternative complement pathway) immediately posttransplantation. Transplanted hearts were harvested at 12 and 48 h for analysis. Both inhibitors resulted in a significant reduction in myocardial IRI, as measured by histology and serum cardiac troponin I levels. Furthermore, compared with untreated controls, both inhibitors reduced graft complement deposition, neutrophil and macrophage infiltration, adhesion molecule expression (P-selectin, E-selectin, and I-CAM-1), and proinflammatory cytokine expression (TNF-α, IL-1β, KC, and MCP-1). The reduction in myocardial damage and cellular infiltration was not significantly different between CR2-Crry– and CR2-III–treated mice, although adhesion molecule and cytokine levels were significantly lower in CR2-Crry–treated mice compared with CR2-III–treated mice. In conclusion, the alternative complement pathway plays a major contributing role in myocardial IRI after heart transplantation, and local (targeted) complement inhibition has the potential to provide an effective and safe therapeutic strategy to reduce graft injury. Although total complement blockade may be somewhat more efficacious in terms of reducing inflammation, specific blockade of the alternative pathway is likely to be less immunosuppressive in an already immunocompromised recipient. The Journal of Immunology, 2010, 185: 000–000.

Ischemia reperfusion injury (IRI) is an unavoidable complication in the process of cardiac transplantation, with the donor heart rendered ischemic for prolonged periods prior to implantation into the recipient and subsequent reperfusion (1–3). These processes damage the cardiac graft via activation of innate immune mechanisms, and the severity of this early inflammation and injury is associated with the ferocity and intensity of a subsequent adaptive immune response (4–6). The mechanisms contributing to the development of IRI are complex and multifaceted, but complement has been shown to play an important role in warm myocardial IRI in a nontransplant setting (7). Ischemia and reperfusion result in the exposure of neeoptopites that are recognized by preformed circulating IgM Abs, termed reperfusion Abs, that activate complement via the lectin and classical pathway (8). The alternative pathway can be activated spontaneously, but it also provides an amplification loop for the lectin and classical pathways. Complement activation by any pathway results in the generation of the following: C3a and C5a, inflammatory peptides involved in endothelial activation and immune cell recruitment and activation; C3 opsonins that coat ischemic and injured cells and that are recognized by receptors on immune cells; and the terminal membrane attack complex (MAC) that is directly cytolytic but also proinflammatory at sublytic concentrations (9–12). All of these complement activation products thus contribute to processes that can amplify graft inflammation and injury, which in turn can promote recognition of the graft by effector cells of the adaptive immune system and the development of graft rejection. We and others have hypothesized that inhibition or reduction in the severity of IRI may protect the graft from early immune recognition, reduce the onset of acute rejection, and potentially protect the graft from the development of chronic rejection (13, 14).

Nearly all data supporting an important role for complement in posttransplant IRI has been obtained from studies on renal transplantation (15). However, one recent study addressed the role of complement in IRI in a cardiac transplant setting. This study demonstrated the deposition of complement activation products in transplanted hearts and further showed a protective effect of an anti-C5 minibody in a rat heart transplant model (16). Nevertheless, as the authors concluded, systemic complement inhibition may be suboptimal from a therapeutic standpoint because complement has important immunoprotective functions, and these functions may be of increased significance in an already immuno-
compromised recipient (16). In the current study, we characterize the effect of two targeted complement inhibitory proteins, CR2-Cry (inhibits all complement pathways) and CR2-fH (inhibits the alternative complement pathway), in an isograft model of cardiac transplantation. We have previously shown that these inhibitors target specifically to sites of complement activation and are therapeutically effective at doses that do not significantly affect systemic complement activity or susceptibility to infection (17). In the current study, our focus is on the inflammatory response after graft transplantation, and we use an isogenic pairing to minimize any potential differences in alloimmune responses and in particular any potential differences in allotype responses or titers.

Materials and Methods

Animals

Male adult C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) weighing 25–30 g were used for transplantation studies. Animals were housed under conventional conditions at the Medical University of South Carolina (Charleston, SC). All procedures were approved by the Medical University of South Carolina Committee for Animal Research in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.

Transplant surgery

C57BL/6 mouse hearts were transplanted into the abdomens of C57BL/6 recipients by anastomosis of the donor and recipient aortas and the donor pulmonary artery with recipient inferior vena cavae, as described previously (18). Donor hearts were removed, perfused, and stored in PBS at 4°C for 35 min prior to implantation. Anastomosis time was standardized to 30 min. Animals were randomized into three treatment groups: 1) PBS vehicle control, 2) 0.25 mg CR2-Cry, and 3) 0.4 mg CR2-fH. Animals were treated with inhibitor or control immediately following completion of surgery. Inhibitor dosage was based on previously published dose-response data in other models (17, 19, 20). The CR2-Cry and CR2-fH fusion proteins were produced and purified as described previously (17, 20). Transplanted hearts were explanted 12 or 48 h postimplantation and divided into four cross-sections.

Histopathology

For histological examination, tissue blocks were placed in 10% buffered formaldehyde solution for 48 h before being embedded in paraffin. Four-micrometer heart sections were stained with H&E stain. Sections were scored by a pathologist (M.G.), who was blinded to the experimental group, using a semiquantitative histology scoring system. Sections were scored 0–3 in four categories for evidence of epicardial, myocardial, endocardial damage, and inflammatory cell infiltrate, where 0 = no damage, 1 = mild damage, 2 = moderate damage, and 3 = severe damage. The results are expressed as cumulative scores from 0 to 12. To further quantify evidence of cardiac damage, we measured cardiac enzyme troponin I activities as an index of cardiac damage, using a commercially available assay kit (Life Diagnostics, West Chester, PA).

Complement deposition

Paraffin-embedded heart tissue sections (5 μm) were immunostained for the presence of C3d. Immunohistochemistry staining for C3d was performed using an Ab directed against C3d (R&D Systems, Volcano, CA). Ab binding was visualized using the Vector Laboratories ImmunoEdge detection kit and diaminobenzidine chromogen development (Vector Laboratories, Burlingame, CA). Specificity of staining was assessed by omission of primary Ab and the use of isotype controls.

Serum complement inhibition

Blood samples were taken at 12 and 48 h posttransplantation and serum was prepared to assay the effect of each targeted complement inhibitor on serum complement activity. Levels of serum complement inhibition were measured using a previously described method that uses flow cytometric analysis of C3 deposition on either zymosan A particles (Sigma-Aldrich, St. Louis, MO) for alternative pathway activity, or on Ab-sensitized CHO cells for classical pathway activity (17).

Immunohistochemistry

The presence of neutrophils (GR1; BD Pharmingen, San Jose, CA), macrophages (mac-3; BD Pharmingen), P-selectin, E-selectin, ICAM-1, and VCAM-1 (BD Pharmingen) was assessed by immunohistochemistry and scored semiquantitatively as described previously (21). In brief, sections were scored from 0 to 3, where 0 = no staining; 1 = weak diffuse endothelial staining < 25% of vessels; 2 = moderate staining involving <50% of vessels; and 3 = strong immunostaining > 50% of vessels are positive.

ELISA and cytokine array

Inflammatory cytokines MCP-1, KC, IL-1β, TNF-α, and IL-6 were measured in heart grafts harvested at 12 and 48 h posttransplantation. Hearts were homogenized, and protein was extracted from tissues as described previously (22). Cytokine levels were measured using ELISA kits (R&D Systems) in accordance with the manufacturer’s recommendations.

Quantitative RT-PCR

Total RNA was extracted from hearts using Qiagen Fibrosis RNA extraction kit (Qiagen, Valencia, CA), according to the manufacturer’s instructions. cDNA was made from 1 μg total RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-time RT-PCR analysis was subsequently performed using the IQ SYBR Green Supermix kit (Bio-Rad) following the manufacturer’s protocols. Analyses were performed using My IQ Real-Time detection system (Bio-Rad) using intron-spanning primers specific for ICAM-1 (forward, 5'-GGTGCTGGATTGCTTCTAA-3'; reverse, 5'-TTCAGAGGCAGAAAACAGC-3'), VCAM-1 (forward, 5'-CCCCACCAACAGGGCAAGATGT-3'; reverse, 5'-CGAGAGTTTTGGGACGTGT-3'), E-selectin (forward, 5'-AGCTACCATGGACACGACG-3'; reverse, 5'-C-GCAAGTCTCCAGCTGGT-3'), P-selectin (forward, 5'-ATGCCCTGGCTACTGGACACT-3'; reverse, 5'-CTTACGCACCATGAACTGG-3'), TNF (forward, 5'-ATGCTGGCTTCACTGGC-3'; reverse, 5'-CTTCATCGCACATGAACTGG-3'), and IL-1β (forward, 5'-AGCTACCATGGACACGAC-3'; reverse, 5'-CCGAAAGTTCTCCAGCTGTT-3'). All reactions were performed in triplicate, and the GAPDH gene was used as an internal control.

Statistics

Data are expressed as mean ± SD. Significant differences between groups were determined by ANOVA, with a Bonferroni correction for continuous variable and multiple groups. A two-tailed Student t test was used for the comparison of a normally distributed continuous variable between two groups, and nonparametric two-tailed statistical analyses were used for histological analyses using GraphPad Prism version 5.00 for Mac OS X. GraphPad Software (GraphPad, San Diego, CA).

Results

Targeted complement inhibition with either CR2-Cry or CR2-fH confers myocardial protection

To investigate the effect of CR2-Cry and CR2-fH on posttransplant IRI, cardiac grafts were assessed for histological evidence of damage at 12 and 48 h after transplantation. Hearts from control-treated recipient mice exhibited key features associated with IRI, including myocyte damage in the epicardium, endocardium, and myocardium. Grafts from control-treated mice also showed evidence of inflammatory cell infiltration and endothelial activation, denoted by endothelial swelling. All of these features were markedly reduced in CR2-Cry– and CR2-fH–treated animals. To quantify these changes in inhibitor-treated mice, H&E-stained heart sections were scored using a semiquantitative cumulative histological scoring system (see Materials and Methods). Treatment with either complement inhibitor was associated with a significant decrease in histology score when compared with controls (Fig. 1A). The severity of histological injury increased significantly between 12 and 48 h in control grafts but not in complement-inhibited animals. The release of the cardiac enzyme cardiac troponin I as an index of cardiac cell damage was measured in serum prepared from blood collected at 48 h posttransplantation. There was a significant increase in cardiac troponin I in control-treated animals compared with sham controls. However, both
CR2-Crry and CR2-fH significantly reduced troponin I levels in recipient mice (Fig. 1B).

**CR2-Crry and CR2-fH ameliorate complement deposition in grafts**

Complement activation products are deposited in both human and animal grafts early after heart transplantation, and they can be detected for up to 3 wk posttransplantation (16, 23, 24). We investigated the effect of CR2-Crry and CR2-fH on C3d deposition in grafts at 12 and 48 h posttransplant. C3d staining was localized to endothelial cells and myocytes at 12 h (Fig. 2) and 48 h (data not shown) in grafts from vehicle control-treated mice. In contrast, C3d deposition was undetectable in grafts from CR2-Crry– and CR2-fH–treated mice at both 12 h (Fig. 2) and 48 h (data not shown) after transplant. C3d staining pattern and intensity was similar at 12 and 48 h posttransplant.

**Complement inhibition attenuates inflammatory cell infiltration**

Semiquantitative histological assessment demonstrated an increase in innate inflammatory cell infiltrate in cardiac grafts from control-treated mice. Complement activation products C3a and C5a are known to play important roles in the recruitment of immune cells to sites of inflammation, and we assessed the effect of CR2-Crry and CR2-fH on neutrophil and macrophage infiltration into grafts. Neutrophils and macrophages were present in all graft sections analyzed, with cells localized to vascular areas, spread between myocytes, and present in larger numbers at the epicardial surface. The distribution of both cell types was not significantly different between the different groups. However, compared with control-treated mice, there was a significant reduction in the numbers of both neutrophils and macrophages in grafts isolated from mice treated with either CR2-Crry or CR2-fH (Fig. 3).

**Complement inhibition reduces adhesion molecule expression**

Numerous studies have highlighted the importance of adhesion molecule expression in inflammatory cell infiltration and graft rejection (1, 25, 26). Because complement activation products have variously been shown to influence the expression of different adhesion molecules, we determined the effect of total complement blockade versus alternative pathway blockade on the expression profiles of P-selectin, E-Selectin, ICAM-1, and VCAM-1 in grafts at 12 and 48 h after transplant. Overall, both CR2-Crry and CR2-fH reduced the expression level of all four adhesion molecules analyzed. The most pronounced reduction in expression levels was seen for P-selectin, with both inhibitors significantly reducing P-selectin expression at both time points of analysis (Fig. 4A). With regard to the other adhesion molecules, only E-selectin expression was significantly reduced by CR2-fH treatment (at the 12-h time point), although there was a strong trend toward reduced expression for ICAM-1 and VCAM-1 (Fig. 4B–D). In contrast, CR2-Crry treatment resulted in a significant reduction in the expression of E-selectin, ICAM-1, and VCAM-1, with the exception of ICAM-1 at 48 h analysis (Fig. 4B–D). Taken together, these data indicate that total blockade of C3 activation is more effective than alternative pathway blockade for providing protection from endothelial activation and suggest a contribution of the classical and/or lectin pathway to adhesion molecule expression.

**Complement inhibition reduces inflammatory cytokine expression**

Previous studies have demonstrated that graft cytokine expression levels change dramatically after transplantation, with different cytokines peaking at different times posttransplant (27). We analyzed TNF-α, IL-1β, MCP-1, and KC in protein extracted from grafts isolated at 12 and 48 h posttransplantation. All cytokine expression levels were normalized by total protein concentrations. At 12 h posttransplant, there was a significant increase in all measured cytokines in grafts from control-treated recipients. However, compared with control-treated mice, levels of all cytokines were significantly reduced in both CR2-Crry– and CR2-fH–treated mice (Fig. 5). Expression levels of TNF-α and IL-1β were significantly lower in CR2-Crry–treated mice compared with CR2-fH–treated mice. By 48 h after transplantation, cytokine levels in all groups were not significantly different to sham baseline levels (Fig. 5).

**Complement inhibition reduces inflammatory cytokine and adhesion molecule gene transcription**

To corroborate protein analysis of adhesion molecule and cytokine expression, we also analyzed transcript expression in grafts harvested at 12 and 48 h after transplant. There was some divergence between protein and gene expression data for ICAM-1 at 12 h and for E-selectin at 48 h posttransplant in CR2-Crry–treated recipients, but otherwise, gene expression data were in keeping with protein data (Fig. 6). IL-1β and TNF-α can both exert transcriptional activation of adhesion molecules through an NF-κB–dependent axis and can also promote inflammation and direct myocyte death. Compared with controls, both CR2-Crry and CR2-fH significantly reduced IL-1β and TNF-α gene expression in grafts at both 12 and 48 h posttransplant (Fig. 6). These data correspond to cytokine protein levels seen 12 h posttransplant, although differences in cytokine protein levels between sham- and inhibitor-treated mice did not reach significance at 48 h posttransplant. Neither inhibitor impacted IL-6 gene expression.

**Therapeutic doses of CR2-Crry and CR2-fH have no significant effect on serum complement activity**

The complement system plays an important role in host immunity, and systemic complement inhibition has been shown to increase susceptibility to infection, a potential limitation for the use of complement inhibition in immunocompromised transplant recipients. We therefore assessed the effect of CR2-Crry and CR2-fH on
serum complement activity in recipient mice. We determined alternative and classical pathway activity by measuring C3 deposition on zymosan particles and Ab-sensitized CHO cells, respectively. At the doses used in the above experiments that provided protection from myocardial IRI, neither inhibitor had any measurable effect on serum complement activity in recipient mice at 12 or 48 h posttransplant (Fig. 7). We have previously shown that the circulatory half life of both CR2-Crry (17) and CR2-fH (20) is ∼8.5 h and that both inhibitors target to sites of complement activation in vivo.

Discussion
IRI occurs in all solid organ transplants, with the length of ischemia correlated to graft outcome (14, 28). The process of transplantation exposes the donor organ to periods of cold ischemia, incurred during organ transportation, and a period of warm ischemia associated with organ implantation into the recipient. The complement system has been implicated in the pathogenesis of IRI in the nontransplant setting, and clinical cardiac transplantation studies have highlighted a significant correlation between complement deposition early post transplant and subsequent graft rejection (24). Given these correlations, treatments directed at inhibiting IRI, and specifically at inhibiting complement activation, have attracted interest as potential therapeutic interventions. A key challenge is the application of a therapeutic strategy that minimizes any impact on host immune or homeostatic functions. In this study, we have used a clinically relevant cardiac transplant model that incorporates cold and warm ischemia to investigate whether the complement system plays a role in posttransplant IRI and whether the application of targeted therapeutics can

![FIGURE 2](image_url)

**FIGURE 2.** C3d deposition in grafts isolated from mice treated with complement inhibitors. C3d deposition in grafts was analyzed by immunohistochemistry at 12 h posttransplantation. C3d deposition was localized to endothelial cells and myocytes in control PBS treated mice (A) (brown staining). No immunostaining was detected in control PBS-treated mice with isotype control Ab (B). Animals treated with either CR2-Crry (C) or CR2-fH (D) showed no evidence of C3d deposition. Representative images of three separate experiments in which n = 5. Original magnification ×10.

![FIGURE 3](image_url)

**FIGURE 3.** Effect of complement inhibition on the infiltration of neutrophils and macrophages into grafts. Neutrophils (A) and macrophages (B) were quantified on immunostained sections by counting five high-power fields. Grafts were isolated 48 h after transplant. Results are expressed as mean ± SD; n = 10 for all groups. *p < 0.01 versus control group.

![FIGURE 4](image_url)

**FIGURE 4.** Effect of complement inhibition on the expression of adhesion molecules in grafts. Recipient mice were treated with PBS (control), CR2-Crry, or CR2-fH, and grafts isolated 12 or 48 h after transplant. Expression of P-selectin (A), E-selectin (B), ICAM-1 (C), and VCAM (D) was examined by immunohistochemistry and scored on a scale of 0–3. Results are expressed as mean ± SD; n = 6 for all groups. °p < 0.01; *p < 0.05 versus vehicle control group.
significantly reduce damage while maintaining normal systemic complement function.

Pharmacological blockade of complement has been shown to reduce IRI following organ transplantation in various rodent models, but only a single study has addressed myocardial IRI post-transplantation. In this previous study, systemic inhibition with an anti-C5 minibody reduced myocardial IRI in a rat isograft model (16). In another study, pretreatment of the donor heart with University of Wisconsin solution containing small interfering RNA targeting TNF-α, Fas, and C3 resulted in improved graft outcome after prolonged cold storage, but given the triple therapeutic approach, it is not possible to assess the relative contribution of C3 silencing in this model (16). Myocardial IRI in a nontransplant setting with warm ischemia, however, has been more extensively studied with regard to the role of complement. In a seminal study, soluble CR1 was shown to significantly reduce inflammation and infarct size in a rat model of IRI (29). CR1, like Crry, promotes decay acceleration of the classical and alternative pathway C3 convertases and acts as a cofactor for factor I-mediated proteolysis of C3b and C4b. Each of these activities serves to block the subsequent activation of new C3 molecules (fH acts by promoting decay acceleration of the alternative pathway C3 convertase and as a cofactor for factor I-mediated proteolysis of C3b). Subsequent studies using C6-deficient animals or animals treated with anti-C5 Ab or C5a receptor antagonist indicate an important role for the terminal complement activation products C5a and/or the MAC in warm myocardial IRI (30–33). More recently, it has been shown that myocardial IRI in a nontransplant setting is dependent on IgM and the lectin pathway (34), and mice deficient in the classical or alternative pathway are not protected from myocardial IRI (35–37). In a transplant setting, however, and under therapeutic conditions of complement inhibition (as opposed to deficiency), we show in this paper an important role for the alternative complement pathway in myocardial IRI. Inhibiting all complement activation pathways or specifically inhibiting the alternative pathway was similarly effective at reducing posttransplant myocardial injury, although CR2-
Crry was more effective than CR2-fH at reducing the expression of certain inflammatory markers. This finding is in line with the increasing recognition that the alternative pathway plays a key role in causing tissue injury in a variety of inflammatory and ischemic conditions, even when there is dependence on the classical or lectin pathways for initiating complement activation (20, 38).

Clinical and animal studies indicate an important role for adhesion molecule expression in the infiltration of both innate immune cells and lymphocytes (1, 39, 40), and although in the current study both inhibitors reduced adhesion molecule expression, CR2-Crry had a more profound effect than CR2-fH. Although this difference did not appear to impact innate cellular infiltrate, it is possible that lymphocyte infiltration and immune priming may be differently impacted in an allograft. In this context, the absence of allograft ICAM-1 has been shown to attenuate alloantigen-specific T cell priming with an associated delay in the onset of rejection (39). Similar correlations have also been reported for P-selectin-specific expression, with deficiency associated with reduced acute rejection, although deficiency appears to exacerbate vasculopathy (25, 41).

In our isograft model, both complement inhibitors resulted in a marked reduction in myocyte cytotoxic cytokines TNF-α and IL-1β and in neutrophil and macrophage chemokines KC and MCP-1. However, similar to our findings with adhesion molecule expression, CR2-Crry treatment resulted in a more pronounced reduction in the level of these molecules compared with CR2-fH treatment. TNF-α and IL-1β can influence adhesion molecule expression via NF-κB activation, and the difference between CR2-Crry and CR2-fH treatment on adhesion molecule expression may be mediated via the effect of the inhibitors on cytokine expression. However, complement activation products can also directly modulate adhesion molecule expression, and complement inhibition likely affects adhesion molecule expression via both direct and indirect complement-dependent mechanisms.

A potential problem in the translation of a complement inhibitory strategy to the clinic is the immunosuppressive effect of systemic complement inhibition in an already immunocompromised recipient. Although infection is not currently a concern in transplant recipients, current immunosuppressive drugs inhibit adaptive T cell responses, and the effect of additionally inhibiting an important innate immune mechanism (i.e., complement) is not known. Strategies investigated to alleviate potential concerns of systemic complement inhibition include treatment of the donor organ with a complement inhibitor prior to transplantation and inhibition of the terminal complement pathway with anti-C5 Ab therapy. However, although anti-C5 therapy (blocks C5a and the MAC) is effective at reducing myocardial IRI following transplantation, C5a has important roles in host defense, and C3 deposition in the graft still occurs (16). Furthermore, although C3 deposition after anti-C5 treatment does not appear to influence IRI, it may have ramifications in the priming of an alloimmune response. A number of clinical studies have shown correlations between C4d and C3d deposition and the subsequent development of acute rejection (24, 42). C3 opsonins (iC3b, C3d, and C3dg) are ligands for receptors on dendritic cells, macrophages, and B cells, and these opsonins may facilitate or amplify humoral immune responses directed toward the graft. Furthermore, local production of C3a and C5a have been shown to be important in dendritic cell maturation and priming of T cell responses (43, 44). In models of allergy and transplantation, the presence of C5a in the local environment with dendritic cells leads to a more aggressive T cell response, due largely to upregulation of costimulatory molecules thought to be mediated by C3a/C3aR ligation (44, 45). Thus, although anti-C5 therapy may inhibit IRI, the presence of C3 activation products may promote antigraft immunity.

In the current study, we demonstrate that inhibitors of C3 activation are effective at reducing myocardial damage posttransplant. The data show an important role for the alternative pathway in myocardial IRI, and a potential advantage of specifically inhibiting the alternative pathway is that host defense and homeostatic mechanisms mediated by the classical and lectin pathways will remain intact. Nevertheless, by targeting complement inhibition to the site of complement activation (the isograft), neither CR2-fH nor CR2-Crry had any measurable effect on serum complement activity 12 or 48 h after graft implantation, even though C3d deposition in the graft was undetectable. Whether the greater reduction in inflammatory markers seen with CR2-Crry compared with CR2-fH translates to an enhanced reduction in allograft rejection remains to be determined. Further studies in an allograft model of heart transplantation would address this and, together with the current data, would provide further information on the contribution of complement-dependent myocardial IRI to graft immunogenicity and rejection.

In conclusion, we demonstrate the efficacy of two targeted complement inhibitors at protecting cardiac isografts from IRI and further demonstrate a key role for the alternative complement pathway in posttransplant IRI under therapeutic conditions. Total complement blockade (CR2-Crry) was more effective than alternative pathway blockade (CR2-fH) at reducing the expression of certain inflammatory molecules, but neither inhibitor had any effect on systemic complement activity 12 or 48 h after transplant, a potential benefit in an already immunocompromised patient.

Acknowledgments
We thank Emily Paulling for support with histology work and Efrain Martinez for production of the recombinant proteins.

Disclosures
The authors have no financial conflicts of interest.

References


